Clinical Trail 1

临床试验1

• 批准号: 10242556
• 负责人: GLENN T FURUTA
• 金额: $ 13.82万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-16 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10242556
• 关键词: 2019-nCoV; Adult; Affect; Airway Disease; Asthma; Award; Biological; COVID-19; Child; Clinical; Clinical Research; Communicable Diseases; Communities; Data; Disease; Enrollment; Epidemiology; Exposure to; Family; Family member; Funding; Gastrointestinal Diseases; Grant; Human; Human Resources; Hypersensitivity; Infection; Lung diseases; Parents; Participant; Pediatric Research; Pediatric cohort; Pediatrics; Predisposition; Procedures; Protocols documentation; Research Personnel; Risk Factors; Science; Site; Source; Surveys; United States National Institutes of Health; Viral Respiratory Tract Infection; Work; access restrictions; allergic airway disease; design; epidemiologic data; gastrointestinal; health care availability; infection burden; infection rate; prospective; research study; response; sample collection; surveillance study; virology

Project Summary/Abstract This Consortium of Eosinophilic Gastrointestinal Researchers (CEGIR) study will enroll approximately 150 families to assess how SARS-COV-2 differentially affects children with Eosinophilic Gastrointestinal Disorders (EGIDs) compared to children without these disorders. The proposed work is part of the larger Human Epidemiology and Response to SARS-CoV-2 (HEROS) study that allows a comparison between children with atopic conditions and children without those conditions. Although asthma has not been identified as a clear risk factor for severe COVID-19 disease, there is evidence that children with asthma and other atopic conditions have increased susceptibility to viral respiratory infections (Esquivel et al, AJRCCM, PMC5649984) and that viral respiratory infections may result in worsening of underlying airway disease (Jartti et al, J Allergy Clin Immunol, PMID 28987219). No data currently exist as to whether this is true for SARS-CoV-2 infection or whether allergic airway disease could be protective. Enrolled families will participate for 6 months completing surveys and biological sample collections. These children and their families are already enrolled in the CEGIR NIH funded studies and therefore will overcome many challenges for clinical study implementation. This proposed work remains in scope to the parent award and is responsive to the NOT-AI-20-031.

项目摘要/摘要 嗜酸性胃肠道研究人员（CEGIR）研究将招募约150个联盟 家族评估SARS-COV-2如何差异影响嗜酸性胃肠道的儿童 与没有这些疾病的儿童相比，疾病（EGID）。拟议的工作是较大的一部分 人类流行病学和对SARS-COV-2（HEROS）研究的反应，该研究允许比较 患有特色疾病的儿童和没有这些条件的孩子。虽然哮喘不是 被确定为严重Covid-19疾病的明显危险因素，有证据表明哮喘儿童 和其他特应特征性疾病对病毒呼吸道感染的敏感性增加（Esquivel et AL，AJRCCM，PMC5649984），并且病毒呼吸道感染可能导致下面的恶化 气道疾病（Jartti等，J Allergy Clin Immunol，PMID 28987219）。目前没有数据 SARS-COV-2感染是否正确，还是过敏性气道疾病 保护的。招收的家庭将参加6个月完成调查和生物样本 收藏。这些儿童及其家人已经在Cegir NIH资助的研究中注册 因此，将克服临床研究实施的许多挑战。这项建议的工作 仍然是父母奖的范围，并且对非AI-20-031的反应。